- AuthorisedTherapeutic exploratory (Phase II)
A phase 2, three-arm, randomized study of the efficacy of intratumorally administered L19IL2 or L19TNF or L19IL2/L19TNF, all in combination with systemic anti-PD1 pembrolizumab, in stage III and IV unresectable melanoma patients with resistance to or progressing upon anti-PD1 checkpoint inhibitors and with presence of injectable metastases
This study looks at new ways to treat advanced melanoma, a type of skin cancer. It combines a standard cancer drug, pembrolizumab, with injections directly into the cancer. Researchers want to see if these new combinations can shrink tumours in people whose cancer hasn’t responded well to previous treatments.
For: Patients with diagnosis of unresectable clinical stage III or IV metastatic melanoma · with presence of injectable cutaneous · subcutaneous or nodal lesions and resistant to or progressing upon anti-PD1 immunotherapyItaly · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II study of intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patients with presence of injectable lesions.
This study is investigating a new treatment for certain skin cancers that have not spread. It uses two special medications, Darleukin and Fibromun, injected directly into the skin cancer. It aims to see how well these medications shrink or get rid of the cancer.
For: Patients with high-risk · locally advanced (non-metastatic · node negativePoland · Germany